Journal of Shandong University (Health Sciences) ›› 2024, Vol. 62 ›› Issue (12): 43-48.doi: 10.6040/j.issn.1671-7554.0.2024.0174
• Clinical Pharmaceutical Research and Evaluation • Previous Articles
LIN Xiaoqian*, FENG Maoyan*, MOU Zheng
CLC Number:
| [1] Chen XW, He ZX, Zhou ZW, et al. An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus[J]. Clin Exp Pharmacol Physiol, 2015, 42(12): 1225-1238. [2] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020版)[J]. 中华糖尿病杂志, 2021, 13(4): 317-411. Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China(2020 edition)[J]. Chin J Diabetes Mellitus, 2021, 13(4): 317-411. [3] Sinclair A, Saeedi P, Kaundal A, et al. Diabetes and global ageing among 65-99-year-old adults: findings from the International Diabetes Federation Diabetes Atlas, 9th edition[J]. Diabetes Res Clin Pract, 2020, 162: 108078. doi:10.1016/j.diabres.2020.108078. [4] Proença C, Ribeiro D, Freitas M, et al. A comprehensive review on the antidiabetic activity of flavonoids targeting PTP1B and DPP-4: a structure-activity relationship analysis[J]. Crit Rev Food Sci Nutr, 2022, 62(15): 4095-4151. [5] Karagiannis T, Boura P, Tsapas A. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review[J]. Ther Adv Drug Saf, 2014, 5(3): 138-146. [6] 中国医师协会内分泌代谢科医师分会. DPP-4抑制剂临床应用专家共识[J]. 中华内分泌代谢杂志, 2018, 34(11): 899-903. Chinese Endocrinologist Association, Chinese Medical Doctor Association. Clinical application of DPP4 inhibitors: a Chinese expert consensus [J]. Chinese Journal of Endocrinology and Metabolism, 2018, 34(11): 899-903. [7] Rummey C, Metz G. Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site[J]. Proteins, 2007, 66(1): 160-171. [8] Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences[J]. Drugs, 2011, 71(11): 1441-1467. [9] 母义明, 朱大龙, 黄仲义. DPP-4抑制剂利格列汀的疗效与安全性评价[J]. 药品评价, 2016, 13(19): 19-27, 34. MU Yiming, ZHU Dalong, HUANG Zhongyi. Evaluation on clinical efficacy and safety of DPP-inhibitor linagliptin[J]. Drug Evaluation, 2016, 13(19): 19-27, 34. [10] 陈莉明. 二肽基肽酶Ⅳ抑制剂类口服降糖药的药化性质和药理活性综合比较分析[J]. 中华糖尿病杂志, 2016, 8(8): 508-510. [11] Feng J, Zhang ZY, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV[J]. J Med Chem, 2007, 50(10): 2297-2300. [12] Sim AY, Barua S, Kim JY, et al. Role of DPP-4 and SGLT2 inhibitors connected to alzheimer disease in type 2 diabetes mellitus[J]. Front Neurosci, 2021, 15: 708547. doi:10.3389/fnins.2021.708547. [13] de Monte SM. Type 3 diabetes is sporadic Alzheimers disease: mini-review[J]. Eur Neuropsychopharmacol, 2014, 24(12): 1954-1960. [14] Chen SY, Zhou M, Sun J, et al. DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling[J]. Neuropharmacology, 2019, 157: 107668. doi:10.1016/j.neuropharm.2019.107668. [15] Ide M, Sonoda N, Inoue T, et al. The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation[J]. PLoS One, 2020, 15(2): e0228750. doi:10.1371/journal.pone.0228750. [16] Zeng XD, Li XH, Chen ZB, et al. DPP-4 inhibitor saxagliptin ameliorates oxygen deprivation/reoxygenation-induced brain endothelial injury[J]. Am J Transl Res, 2019, 11(10): 6316-6325. [17] Pham TK, Nguyen THT, Yi JM, et al. Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice[J]. Exp Mol Med, 2023, 55(4): 767-778. [18] Akashi N, Umemoto T, Yamada H, et al. Teneligliptin, a DPP-4 inhibitor, improves vascular endothelial function via divergent actions including changes in circulating endothelial progenitor cells[J]. Diabetes Metab Syndr Obes, 2023, 16: 1043-1054. doi:10.2147/DMSO.S403125. [19] Lee JM, Yoo IK, Lee JM, et al. Dipeptidyl-peptidase-4(DPP-4)inhibitor ameliorates 5-flurouracil induced intestinal mucositis[J]. BMC Cancer, 2019, 19(1): 1016. [20] Olivares M, Neyrinck AM, Pötgens SA, et al. The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice[J]. Diabetologia, 2018, 61(8): 1838-1848. [21] Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors[J]. Clin Pharmacokinet, 2012, 51(8): 501-514. [22] Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus[J]. N Engl J Med, 2013, 369(14): 1317-1326. [23] Alshamrani AA, Al-Hamamah MA, Albekairi NA, et al. Impacts of the DPP-4 inhibitor saxagliptin and SGLT-2 inhibitor dapagliflozin on the gonads of diabetic mice[J]. Biomedicines, 2023, 11(10): 2674. [24] Kim SH, Jung E, Yoon MK, et al. Pharmacological profiles of gemigliptin(LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo[J]. Eur J Pharmacol, 2016, 5(788): 54-64. [25] Jain MR, Joharapurkar AA, Kshirsagar SG, et al. ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of type 2 diabetes mellitus[J]. Br J Pharmacol, 2017, 174(14): 2346-2357. [26] Wang L, Li XP, Kong Y, et al. Pharmacokinetics, tissue distribution and excretion of compound 6c, a novel DPP-4 inhibitor, following intragastric administration in rats by ultra-performance liquid chromatography-tandem mass spectrometry[J]. Eur J Pharm Sci, 2022, 173: 106162. doi:10.1016/j.ejps.2022.106162. |
| [1] | LI Jinquan, GAO Meifang, YAN Fei, DONG Ming. Frequency and risk factors of muscle cramp in 136 cases of type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2023, 61(5): 20-24. |
| [2] | HAN Mei, MENG Weijing, TAO Zikun, YANG Xi, XU Yaqi, MU Huaxia, BU Weixiao, WANG Suzhen, SHI Fuyan. Causal mediation analysis with multiple-mediator of hypertension and depression between type 2 diabetes mellitus and cognitive function based on G-computation [J]. Journal of Shandong University (Health Sciences), 2023, 61(10): 101-108. |
| [3] | MA Xiang, ZHAO Feiyan. Status and progress of oocyte cryopreservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 19-23. |
| [4] | LI Tao, YANG Chunlin, DU Tong, LI Heng, WANG Congcong, LI Xiaoli, DUAN Ruisheng,ZHANG Peng. Effects of diabetes mellitus on the subsets and function of NK cells in myasthenia gravis [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 31-36. |
| [5] | WANG Chuanxin. Liquid biopsy of tumor [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 64-71. |
| [6] | LYU Li, JIANG Lu, CHEN Shihong, ZHUANG Xianghua, SONG Yuwen, WANG Dianhui, AN Wenjuan, LI Qian, PAN Zhe. Related factors of osteoporosis in 210 postmenopausal women with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 19-25. |
| [7] | ZHENG Fengjie, SONG Yuwen, SUN Aili, PAN Zhe, WANG Dianhui, LOU Nengjun, LYU Li, ZHUANG Xianghua, CHEN Shihong. Correlation between diabetic peripheral neuropathy and sarcopenia [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 38-44. |
| [8] | LIU Ping, SONG Yuwen, WANG Ping, TIAN Guangwei, ZHENG Fengjie, LYU Li, DU Jiaojiao, ZHANG Jing, ZHUANG Xianghua, CHEN Shihong. Correlation between vitamin D deficiency and depression in patients with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 51-56. |
| [9] | XIAO Yang, TAO Yu, WANG Fangyi, LIANG Yuxiu, ZHANG Jin, JI Xiaokang, WANG Zhiping. Association between PM2.5 and PM10 exposure with gestational diabetes mellitus in certain areas of Shandong Province [J]. Journal of Shandong University (Health Sciences), 2021, 59(12): 101-109. |
| [10] | WANG Yuyu, GAO Li, CHEN Shaohua. Association between cognitive impairment and thyroid function after acute ischemic stroke in 94 patients with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2020, 58(5): 56-61. |
| [11] | JIN Haiyan, ZHANG Yan, MA Xiaoli, HAN Yu, ZHAO Huichen, LIU Yuantao, ZHANG Yuchao. Expressions of miR-122 and miR-33a in patients with type 2 diabetes complicated with coronary artery disease [J]. Journal of Shandong University (Health Sciences), 2020, 58(3): 94-98. |
| [12] | TANG Bo, SHAO Jing, CUI Jing, SUN Jianping. A mechanism study on the association of type 2 diabetes and high-density lipoprotein [J]. Journal of Shandong University (Health Sciences), 2020, 58(3): 99-106. |
| [13] | HUANG Ping, SHANG Hongguo. Clinical application of digital implant guide in the absence of continuous multiple teeth in the mandibular posterior tooth area [J]. Journal of Shandong University (Health Sciences), 2020, 58(2): 60-63. |
| [14] | XU Ling, SUN Yan, CHEN Liang, WANG Xiwen. Application of mixed reality technique in the resection of benign lateral skull base tumor [J]. Journal of Shandong University (Health Sciences), 2020, 58(1): 31-38. |
| [15] | TIAN Zhongyan, LI Yuqian, LIU Xiaotian, SHI Yuanyuan, ZHANG Haiqing, ZHANG Xia, QIAN Xinling, YIN Lei, ZHAO Jingzhi, WANG Chongjian. Relationship between PSMD6 gene rs831571 locus polymorphism and the susceptibility of T2DM: a case-control study [J]. Journal of Shandong University (Health Sciences), 2018, 56(7): 51-56. |
|
||
